Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **M2-2 protein** is a non-structural regulatory protein expressed by the M2 gene of both Respiratory syncytial virus and Human metapneumovirus. It governs the switch between **viral mRNA transcription and genome replication**, acting as a negative regulator of RNA synthesis during infection[4][2]. M2-2 interacts with ribosomal and chaperone proteins, modulates viral replication and translation, and is targeted for proteasome-mediated degradation[1]. Deletion of M2-2 attenuates viral replication and is a promising strategy for the development of live attenuated vaccines for RSV and HMPV[2].
Not applicable; M2-2 is not a direct drug target. However, attenuated viruses lacking M2-2 are being developed as live vaccines, as deletion leads to an attenuated but immunogenic phenotype.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Respiratory syncytial virus M2-2 protein (M2-2).